Voyager Therapeutics, Inc. — FY 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. This is a clinical-stage gene therapy company; it had no approved products and no product-sales revenue. Financial statements were audited by Ernst & Young, which issued an unqualified opinion.
Business context and pipeline
Voyager develops AAV gene therapies for severe central nervous system diseases. Its lead candidate, VY-AADC01 for advanced Parkinson’s disease, was in an open-label Phase 1b trial; the company targeted human proof-of-concept data in Q4 2016. Four other programs—monogenic ALS, Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy—were preclinical. Management aimed to file an IND for an existing preclinical program in 2017.
Key financial metrics
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Collaboration revenue | $17.3 million | None |
| Research and development expense | $27.7 million | $8.9 million |
| General and administrative expense | $9.9 million | $5.5 million |
| Operating loss | $20.3 million | $14.4 million |
| Net loss | $29.7 million | $16.3 million |
| Net loss attributable to common stockholders | $38.3 million | $17.7 million |
| Cash, cash equivalents and marketable securities at year-end | $224.3 million | $7.0 million |
| Working capital at year-end | $172.0 million | $5.9 million |
| Total assets / total liabilities at year-end | $229.5 million / $60.4 million | $11.5 million / $10.3 million |
FY 2015 operating cash flow was positive $41.3 million, primarily reflecting the $65.0 million Genzyme upfront cash payment and increased deferred revenue; it should not be read as recurring operating cash generation. Investing cash flow was negative $194.8 million, largely from purchases of marketable securities; financing cash flow was positive $177.7 million, including IPO and preferred-stock proceeds. No borrowings or debt balance are identified in the provided filing text. The company reported no product gross margin; collaboration revenue was its only revenue source.
At December 31, 2015, deferred revenue was $55.0 million, including $19.6 million current and $35.4 million non-current. Management expected existing cash, equivalents and marketable securities to fund operating expenses and capital needs into 2019, based on its current plan.
Material changes and unusual items
- Revenue rose from zero in 2014 to $17.3 million, entirely from the Genzyme collaboration. Research and development expense increased by $18.8 million as the company expanded research, platform development, manufacturing work and clinical activity.
- Net loss increased by $13.4 million. Other expense included a $9.75 million non-cash fair-value remeasurement loss on Series A preferred-stock tranche rights; the liability was settled when the final tranche was issued in February 2015.
- The November 2015 IPO raised $72.9 million net. Preferred stock converted into common stock at the IPO; this materially changed the share count and makes per-share comparisons less comparable. Common-stockholder loss also reflects preferred-stock accretion and accrued dividends.
- For Q4 2015, collaboration revenue was $4.9 million, operating expenses $12.4 million, and net loss attributable to common stockholders $8.8 million. Q4 2014 had no collaboration revenue, operating expenses of $4.5 million and common-stockholder loss of $5.2 million.
- Cash and marketable securities were mainly invested in U.S. Treasury and government-agency securities. The year-end unrealized loss on available-for-sale securities was $0.25 million. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Outlook, risks and contingencies
- Management expected higher R&D and public-company costs and continued operating losses; it did not provide revenue or profitability guidance and did not expect product-sales revenue in the foreseeable future.
- Genzyme provided $65.0 million upfront cash, a $30.0 million equity investment and an in-kind commitment of up to $5.0 million. Voyager retained U.S. rights to VY-AADC01 and VY-FXN01, among other rights, while Genzyme held program options. The filing describes up to $645 million in regulatory and commercial milestones, plus option payments and royalties; its business overview also refers to potential option and milestone payments of up to $745 million.
- Clinical evidence remained early and uncertain. In Phase 1b, the first five-patient cohort showed approximately 21% average putamen coverage and no meaningful efficacy signal to date. Patient 6 in cohort 2 had improved coverage and encouraging three-month interim measures, but management cautioned that these were from one patient in an open-label trial. A patient in cohort 2 experienced pulmonary embolism and related arrhythmia attributed to prolonged surgical immobilization; both events resolved, and risk-mitigation procedures were introduced.
- Key risks include clinical failure or delays, surgical and gene-therapy safety risks, regulatory uncertainty, manufacturing scale-up and cGMP compliance, reliance on third-party manufacturers and collaborators, competition, intellectual-property challenges, and the possibility that additional financing may be needed if plans or costs change.
- In January 2016, after year-end, Voyager extended its existing lease through 2024 and signed a lease for additional Cambridge space. The filing estimates approximately $25 million of lease payments associated with these arrangements, excluded from the year-end contractual-obligations table.
Most important facts for investors to verify
- Whether the Phase 1b trial delivers reproducible putamen coverage, safety and efficacy results, and whether the stated Q4 2016 proof-of-concept target was achieved.
- The composition and duration of the reported cash runway, including actual spending against plan and the timing and conditions of Genzyme option, milestone and royalty payments.
- Whether manufacturing capacity, quality and regulatory readiness advance as planned, including the new facility commitments and related lease costs.
- The terms and accounting for Genzyme collaboration revenue and deferred revenue, and how much future development spending Voyager must fund before option exercise.
- The scale of equity compensation and potential dilution: FY 2015 stock-based compensation was $4.0 million, with $36.8 million of unrecognized compensation expense at year-end.
- Potential limits on the use of tax attributes: the company had federal and state NOL carryforwards of $32.1 million and $30.2 million, respectively, and had not completed a Section 382 ownership-change analysis.